2019 Aspen Lung Conference: Exploring new therapeutic pathways in pulmonary hypertension: metabolism, proliferation, and personalized medicine

摘要 PH领域日益认识到肺血管病变存在于肺脏。 高血压(PH)具有肿瘤样特征，包括识别关键的共同病理生理学 并且现在已经在PH患者中催生了化疗药物的临床试验。2019年 托马斯·L·佩蒂·佩蒂·阿斯彭肺会议将探讨肿瘤和PH的共同机制， 总体目标是将我们对细胞代谢、增殖和信号的理解转化为更多 对肥厚症患者的有效治疗。会议的题目是《探索新的治疗途径》。 肺动脉高压：新陈代谢、增殖和个体化药物“。为期四天的会议 将整合基本的、翻译的和临床的方法，同时专注于PH的以下主题：细胞 代谢、低氧信号、细胞异常增殖和个体化药物。我们已经确定了 12位演讲者，他们是各自领域的杰出科学家，他们将就这些问题发表最新的演讲 主题。每场演讲的时长为35分钟，随后是25分钟的讨论 确保活跃的互动，这是本次会议的一个标志。我们特别强调包括 女性和少数民族演讲者(在计划的节目中分别为54%和38%)。 包括受训人员和初级教员，每个人后面都有两个15分钟的口头摘要 最先进的演讲者(总共24人)，将从提交的摘要中挑选出来。会有两张晚间海报 为初级教师和实习生提供进一步演讲机会的课程。最后的演讲是由一位 会议总结者，审查整个会议的影响和共同主题。这次会议 会议记录随后出版，以供广泛传播。两项旅行津贴授予女性 和代表不足的少数抽象申请者基于科学上的卓越。这次会议有 以下目标：1)为领先的基础、翻译和临床研究人员提供一个国际论坛 就肺高压的发病机制和治疗的基本概念进行交流。2)刺激 肺病学、心脏病学和肿瘤学领域之间的相互作用，目的是确定新出现的、 共同的兴趣将导致更有效率和更有成效的研究。3)增进对……的理解 临床和分子PH病理生物学，以便将临床前的发现转化为更有效的、个性化的 治疗。4)挑战并激发学员的科学兴趣，吸引新一代 在PH病理生物学领域的初级调查人员。总而言之，大会有别于 在公共卫生领域的其他会议，作为积极讨论该领域的现状和 明确PH基础研究、翻译研究和临床研究的未来方向。

ABSTRACT The PH field has increasingly recognized that the pulmonary vascular pathology present in pulmonary hypertension (PH) has neoplastic-like features, including the identification of key shared pathophysiology commonalities and has now spawned clinical trials of chemotherapy agents in patients with PH. The 2019 Thomas L. Petty Aspen Lung Conference will explore the common mechanisms found in neoplasia and PH, with the overall goal of translating our understanding of cellular metabolism, proliferation and signaling into more effective therapies for patients with PH. The title of the conference is “Exploring new therapeutic pathways in pulmonary hypertension: metabolism, proliferation, and personalized medicine”. The four days of the conference will integrate basic, translational, and clinical approaches while focusing on the following themes in PH: Cellular Metabolism, Hypoxia Signaling, Aberrant Cellular Proliferation and Personalized Medicine. We have identified 12 speakers who are outstanding scientists in their fields, who will present State of the Art lectures on these topics. Each of these presentations will be 35 minutes in duration, followed by 25 minutes for discussion to ensure a lively interaction which is a hallmark of this conference. We have a particular emphasis on including female and ethnic minority State of the Art speakers (54% and 38% in the planned program, respectively). Inclusion of trainees and junior faculty is emphasized by having two 15-minute oral abstracts following each State of the Art speaker (24 total), that will be selected from submitted abstracts. There will be two evening poster sessions for further presentation opportunities by junior faculty and trainees. The final presentation is by a Conference Summarizer, who reviews the impact and common themes of the entire conference. The conference proceedings are subsequently published for widespread dissemination. Two travel grants are awarded to female and under-represented minority abstract applicants based on scientific excellence. The conference has the following objectives: 1) To provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding fundamental concepts in the pathogenesis and treatment of PH. 2) To stimulate interactions between the fields of pulmonology, cardiology and oncology with the goal of identifying emerging, shared interests that will lead to more efficient and productive research. 3) To advance our understanding of clinical and molecular PH pathobiology in order to translate preclinical findings to more effective, personalized therapies. 4) To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the field of PH pathobiology. In summary, the conference distinguishes itself from other conferences in the PH field by serving as a “think tank” to actively discuss the current state of the field and identify the future directions for basic, translation and clinical research in PH.